In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Strikes A Deal With Isis For Antisense Technology

This article was originally published in The Pink Sheet Daily

Executive Summary

Biogen has agreed to pay an upfront and milestones for an option to license Isis' Phase I antisense compound to treat a rare spinal disorder.

You may also be interested in...



Isis Builds On Platform Strategy With Fourth Biogen Tie-Up

The antisense company has made it clear that it will not pursue commercialization of its own drugs, but intends to partner out all of its assets, while still retaining the most advantageous economics. Its fourth agreement with Biogen Idec, a strategic collaboration, is the most extensive and lucrative to date with the partner.

Isis Teams Up With Roche In Early-Stage Huntington’s Deal

The biotech’s latest tie-up is another validation of its technology that could help it garner further attention – and better economics – for some of its late-stage programs.

Isis Moves SMA Drug Forward As Market Interest For The Rare Disease Expands

Spinal muscular atrophy is a rare disease that affects a small patient population of children. Isis is ready to move its compound into mid-stage testing after positive Phase I results, but the biotech isn’t the only company exploring the field.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073215

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel